GlaxoSmithKline to establish third global center for vaccine research in Rockville, Md.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GLAXOSMITHKLINE plans to establish its third center for vaccine research and development in Rockville, Md. The site follows existing R&D centers in Rixensart, Belgium and Siena, Italy, which GSK acquired from Novartis in March.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login